Cargando…

Nonsurgical treatment for upper eyelid retraction in patients with inactive Graves’ orbitopathy

PURPOSE: To evaluate the effectiveness of incobotulinumtoxinA (Xeomin(®)) in treating upper eyelid retraction in patients with Graves orbitopathy (GO) initially scheduled for surgery via two different application sites. METHODS: This is a comparative, prospective study, conducted at the Department o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vokurka Topljak, Sandra, Galiot Delić, Martina, Mandić, Krešimir, Perić, Sanja, Baretić, Maja, Juri Mandić, Jelena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2023
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805617/ https://www.ncbi.nlm.nih.gov/pubmed/36587368 http://dx.doi.org/10.1007/s10792-022-02625-7

Ejemplares similares

Awareness of EUGOGO guidelines and attitudes regarding smoking in Graves' orbithopathy in Croatia
por: Maja, Baretić, et al.
Publicado: (2021)

Dermis-Fat Graft for Correction of Recurrent Severe Upper Eyelid Retraction in Graves’ Orbitopathy
por: Kuzmanović Elabjer, Biljana, et al.
Publicado: (2018)

Upper eyelid retraction disclosed after edrophonium chloride administration in a patient with Graves’ orbitopathy and myasthenia gravis
por: Kang, Hyera, et al.
Publicado: (2012)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Influence of Clinically Active Graves’ Ophthalmopathy on Spherical Equivalent and Visual Acuity
por: Petrovic Jurcevic, Jasenka, et al.
Publicado: (2022)

Double motion of upper eyelids in Graves’ orbitopathy: an additional sign for detection of thyroid dysfunction or positive thyroid autoantibodies
por: Kakizaki, Hirohiko, et al.
Publicado: (2011)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Graves′ orbitopathy: Management of difficult cases
por: Wiersinga, Wilmar M.
Publicado: (2012)

Endoscopic orbital decompression for Graves’ orbitopathy
por: Lal, Priti, et al.
Publicado: (2013)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Current concepts regarding Graves’ orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2022)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Significance of HLA in the development of Graves’ orbitopathy
por: Stasiak, Magdalena, et al.
Publicado: (2023)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy
por: Woo, Young Jae, et al.
Publicado: (2015)

Planning health care for patients with Graves’ orbitopathy
por: Sasim, Inna V., et al.
Publicado: (2008)

Surgical complications in orbital decompression for Graves' orbitopathy
por: Sellari-Franceschini, S., et al.
Publicado: (2016)

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy
por: Fang, Sijie, et al.
Publicado: (2021)

Serum thyroglobulin is associated with orbitopathy in Graves’ disease
por: Khamisi, S., et al.
Publicado: (2021)

Correction to: Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2021)

Roles of four targets in the pathogenesis of graves' orbitopathy
por: Ren, Ziqiang, et al.
Publicado: (2023)

Atypical Asymmetric Presentation of Severe Graves’ Orbitopathy
por: Gupta, Priyanka, et al.
Publicado: (2023)

Assessment of Choroidal Vascularity in Inactive Thyroid Associated Orbitopathy
por: Pehlivanoglu, Seren, et al.
Publicado: (2023)

Endoscopic intranasal orbital decompression in the course of Graves’ orbitopathy
por: Krzeski, Antoni, et al.
Publicado: (2013)

Association between Polymorphisms in the TSHR Gene and Graves' Orbitopathy
por: Jurecka-Lubieniecka, Beata, et al.
Publicado: (2014)

Not All Orbitopathy Is Graves’: Discussion of Cases and Review of Literature
por: Boddu, Neeraja, et al.
Publicado: (2017)

Teprotumumab: a disease modifying treatment for graves’ orbitopathy
por: Ting, Michelle, et al.
Publicado: (2020)

Factors associated with severity of orbitopathy in patients with Graves' disease
por: Nabi, Tauseef, et al.
Publicado: (2020)

Challenges and perspectives of selenium supplementation in Graves’ disease and orbitopathy
por: Bednarczuk, Tomasz, et al.
Publicado: (2019)

Glucocorticoids in Graves’ orbitopathy: mechanisms of action and clinical application
por: Längericht, Jan, et al.
Publicado: (2020)

Adipocytokines in Graves’ orbitopathy and the effect of high-dose corticosteroids
por: Schovanek, Jan, et al.
Publicado: (2021)

IgG4 as a Biomarker in Graves' Orbitopathy
por: Olejarz, Michał, et al.
Publicado: (2021)

Acute Corneal Hydrops in Keratoconus Patients with Graves’ Orbitopathy
por: Dogan, Aysun Sanal, et al.
Publicado: (2021)

The Clinical Features of Graves' Orbitopathy with Elevated Intraocular Pressure
por: Fan, Shu-Xian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hsgnujm2noet7ei1fh9mnb709v